Marianne P. Allen

Array ( [id] => 14808373 [patent_doc_number] => 20190270796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => THERAPEUTIC AGENT FOR PERIODONTITIS AND COMPOSTION FOR TREATING PERIODONTITIS [patent_app_type] => utility [patent_app_number] => 16/320279 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16320279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023652 [patent_doc_number] => 20170313751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'Methods and Pharmaceutical Composition for the Preservation of Vascular Endothelial Cell Barrier Integrity' [patent_app_type] => utility [patent_app_number] => 15/652675 [patent_app_country] => US [patent_app_date] => 2017-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17109 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15652675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17148411 [patent_doc_number] => 11141463 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-12 [patent_title] => Fusion proteins with extended serum half life [patent_app_type] => utility [patent_app_number] => 16/316410 [patent_app_country] => US [patent_app_date] => 2017-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 24 [patent_no_of_words] => 26415 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17649706 [patent_doc_number] => 11352420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Methods and compositions for PDGF-CC inhibition [patent_app_type] => utility [patent_app_number] => 16/312843 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 34 [patent_no_of_words] => 24961 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19226718 [patent_doc_number] => 12006351 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-11 [patent_title] => Compositions and methods for modifying activity of extracellular MMP-2 [patent_app_type] => utility [patent_app_number] => 16/314227 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 11 [patent_no_of_words] => 12571 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16314227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421281 [patent_doc_number] => 11254723 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => Recombinant human-basic fibroblast growth factor (rh-bFGF) and pharmaceutical composition comprising rh-bFGF [patent_app_type] => utility [patent_app_number] => 16/625308 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 6828 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866211 [patent_doc_number] => 20200140509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => METHOD FOR PRODUCING SOLUBLE RECOMBINANT HUMAN-BASIC FIBROBLAST GROWTH FACTOR (rh-bFGF) [patent_app_type] => utility [patent_app_number] => 16/625191 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14564087 [patent_doc_number] => 20190209650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => METHOD TO IMPROVE THE EFFECTIVENESS OF ANTI-CANCER THERAPIES BY EXPOSING CANCER CELLS TO AN INFLAMMATORY STIMULUS PRIOR TO TREATMENT [patent_app_type] => utility [patent_app_number] => 16/312841 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11987776 [patent_doc_number] => 20170291931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-12 [patent_title] => 'FGF2 TRUNCATIONS AND MUTANTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/617812 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 28842 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15617812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290120 [patent_doc_number] => 10766956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis [patent_app_type] => utility [patent_app_number] => 16/307444 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 63 [patent_no_of_words] => 26315 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971206 [patent_doc_number] => 20170275360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS' [patent_app_type] => utility [patent_app_number] => 15/615197 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 30338 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15615197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971207 [patent_doc_number] => 20170275361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS' [patent_app_type] => utility [patent_app_number] => 15/615281 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 30419 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15615281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058644 [patent_doc_number] => 20170334987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'ANTI-ACTH ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/613414 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 132 [patent_figures_cnt] => 132 [patent_no_of_words] => 143701 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15613414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11962107 [patent_doc_number] => 20170266260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/607581 [patent_app_country] => US [patent_app_date] => 2017-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13552 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15607581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273823 [patent_doc_number] => 20190134196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/305828 [patent_app_country] => US [patent_app_date] => 2017-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12029557 [patent_doc_number] => 20170319656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'HEART FAILURE TREATMENT' [patent_app_type] => utility [patent_app_number] => 15/602646 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12201 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15602646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689567 [patent_doc_number] => 20170355738 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/598420 [patent_app_country] => US [patent_app_date] => 2017-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15598420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14637155 [patent_doc_number] => 10363306 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Cytokines and neuroantigens for treatment of immune disorders [patent_app_type] => utility [patent_app_number] => 15/591893 [patent_app_country] => US [patent_app_date] => 2017-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 19969 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15591893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936480 [patent_doc_number] => 20170240629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'BISPECIFIC ANTIBODIES AND METHODS OF USE IN OPHTHALMOLOGY' [patent_app_type] => utility [patent_app_number] => 15/590176 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51423 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15590176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13139851 [patent_doc_number] => 10087246 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-02 [patent_title] => Anti-PDGF-B antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 15/590172 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40465 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15590172 [rel_patent_id] =>[rel_patent_doc_number] =>)